Astrazeneca ADR Stock
€72.00
Your prediction
Astrazeneca ADR Stock
Pros and Cons of Astrazeneca ADR in the next few years
Pros
Cons
Performance of Astrazeneca ADR vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Astrazeneca ADR | 1.410% | -0.690% | 0.699% | 5.109% | 17.073% | 54.506% | - |
GSK plc ADR | 1.470% | -0.481% | 8.377% | 31.013% | 23.214% | 3.500% | -4.277% |
Bayer AG ADR | -6.430% | -2.963% | -0.758% | -50.000% | -23.837% | -50.000% | -50.000% |
Roche Holding AG ADR | 1.620% | 1.262% | 5.554% | -20.397% | -8.789% | -17.553% | - |
News
This Pharma Stock Is Poised to Keep Outperforming the S&P 500
AstraZeneca (NASDAQ: AZN), recognized as the world's sixth-largest pharmaceutical entity by market capitalization, made a bold proclamation in May 2014. The company set an ambitious goal of
AstraZeneca Plans to Rake in $80 Billion by 2030. Should You Buy the Stock?
AstraZeneca (NASDAQ: AZN) is embarking on a fresh business plan that will see it grow significantly between now and 2030. If it succeeds, it'll be a company that's even more prominent in the global
Forget Johnson & Johnson: Buy This Better Healthcare Stock Instead
Many healthcare investors look at Johnson & Johnson (NYSE: JNJ) and see a good, safe dividend stock. But I see an investment that's full of uncertainty and risk.
The company continually runs into